Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shRNA V0a2 is an experimental short hairpin RNA (shRNA) construct designed to silence the expression of the a2 subunit of the vacuolar H+-ATPase (V-ATPase), which is encoded by the *ATP6V0A2* gene. The V-ATPase is a multi-subunit proton pump responsible for the acidification of intracellular compartments, including lysosomes and the Golgi apparatus. The a2 isoform (V0a2) is specifically localized to the Golgi and is frequently overexpressed in various malignancies, such as breast, ovarian, and prostate cancers. In these contexts, V0a2 contributes to the abnormal glycosylation of surface proteins and promotes an invasive phenotype by modulating the tumor microenvironment and intracellular trafficking. By utilizing RNA interference (RNAi), shRNA V0a2 achieves stable knockdown of the target protein, typically through delivery via lentiviral or adenoviral vectors. This tool is primarily used in preclinical research to investigate the role of pH regulation in oncogenesis and to evaluate the therapeutic potential of targeting the V-ATPase machinery to inhibit tumor cell invasion and growth.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shRNA V0a2.